Cardiome Pharma Corp. and SteadyMed Ltd. announced that the European Medicines Agency (EMA) has approved Cardiome's request to review Trevyent® (treprostinil PatchPump) under the Centralised Authorisation Procedure drug review process. This procedure results in a single marketing authorization that is valid in all 28 European Union (EU) countries as well as 3 European Economic Area (EEA) countries.

Cardiome requested, and was granted, the centralized pathway on the basis that Trevyent represents a significant technical innovation for the potential treatment of pulmonary arterial hypertension (PAH).